Molecular Assessment and Preclinical Studies (MAPS), is a newly formed Core established to assist Cancer Center and University researchers in conducting in vivo (animal) testing of novel anti-cancer therapeutics and monitoring clinical trials by molecular analysis. The MAPS Core grew out of the Cancer Center research retreat in 2004-during which Dr. Weber led a discussion on """"""""developing infrastructure that would assist basic scientists at UVa in translational cancer research."""""""" Since that time, the MAPS Core has emerged as a centralized Core focused at providing Cancer Center investigators access to 1) standardized, cost effective preclinical models, 2) in-house drug development expertise and 3) molecular tools for effective monitoring of targeted therapies in animal and clinical trials. Our ultimate mission is to create novel UVa therapies and monitor cancer trials in order to combat cancer and improve the care of our patients. The MAPS Core is divided into two divisions: molecular assessment and preclinical studies. Molecular assessments offer a wide array of molecular profiling assistance to investigators performing pre-clinical (animal) and clinical (human) trials. These efforts are focused at assisting investigators in: 1) developing custom protein microarrays, 2) standardizing normal mouse tissue arrays for immunoblotting with custom or commercial antibodies, 3) creating a directory of assessable human cancer cell lines and 4) providing cell culture assistance, 5) molecular analysis on human cell lines and tissue samples and 6) educating and training clients in molecular analysis. Preclinical studies will assist investigators, interested in developing new therapies, with a range of activities including: 1) mouse models (efficacy and toxicity assessment), 2) expert technical support in animal cancer model design, animal protocol writing and analysis of drug studies and 3) educating and training clients in the performing animal models and surgical techniques needed for specialized animal studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Virginia
United States
Zip Code
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications